Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP6282 + pilocarpine is a combination drug consisting of ASP6282, an experimental agent, and pilocarpine, a well-established cholinergic agonist. **Pilocarpine** works as a muscarinic receptor agonist, facilitating the outflow of aqueous humor in the eye (primarily used in glaucoma and presbyopia), and stimulates exocrine gland secretion, commonly for dry mouth and Sjögren's syndrome. Its mechanism is via selective muscarinic (acetylcholine) receptor activation[2][3]. **ASP6282** is an experimental agent; although detailed public mechanistic or structural information is limited, it is presumed to be pharmacologically active in ophthalmology when combined with pilocarpine. The combination aims to address ophthalmic conditions such as presbyopia or related indications where muscarinic agonism is beneficial, potentially offering improved efficacy, safety, or pharmacodynamic properties compared to pilocarpine alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASP6282 + pilocarpine.